Table 2. Summary of eMLST, monoclonal antibody typing and antibiotic susceptibility testing results for antibiotic-resistant P. acnes strains.
rRNA mutation(s) | MICb | ||||||||||||
Isolate | Phylotype | Region | Source | Antibodytypinga | Allelic profile | eST | CC | 16 S | 23 S | TC | EM | CL | Erm(X) |
PRP-062 | IA1 | Italy | Acne | IA | 1-1-1-9-1-1-1-1 | 49 | CC1 | − | + (2058) | 32 | ≥256 | 32 | – |
308.2 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | − | 8 | 0.032 | 0.025 | – |
322.2 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | − | 8 | ≥256 | 1 | – |
401.5 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-1-2-2 | 3 | CC3 | + | + (2057) | ≥256 | 4 | 0.5 | – |
411.2 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-1-1 | 1 | CC1 | + | + (2058) | 8 | ≥256 | 16 | – |
413 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-17-33 | 88 | S | + | − | 8 | 0.032 | 0.032 | – |
416.1 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2059) | 8 | ≥256 | 2 | – |
423.1 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | − | 8 | 0.032 | 0.5 | – |
423.3 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | − | 8 | 0.032 | 0.25 | – |
425.1 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 4 | ≥256 | 16 | – |
429.1 | IA1 | Sweden | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | - | 8 | 0.5 | 0.5 | – |
R11883 | IA1 | UK | Blood | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 6 | ≥256 | 32 | – |
R20767 | IA1 | UK | Pus | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 6 | ≥256 | 8 | – |
PRP-002 | IA1 | Australia | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 8 | ≥256 | 8 | – |
PRP-003 | IA1 | UK | Acne | IA | 8-1-1-3-1-1-2-2 | 43 | CC3 | + | − | 24 | <0.016 | 0.016 | – |
PRP-004 | IA1 | UK | Acne | IA | 1-1-1-3-1-1-1-1 | 1 | CC1 | + | − | 8 | <0.016 | 0.023 | – |
PRP-053 | IA1 | Australia | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 3 | ≥256 | 1.5 | – |
PRP-101 | IA1 | USA | Acne | IA | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2059) | ≥256 | ≥256 | 1.5 | – |
PRP-102 | IB | USA | Acne | Atypical | 1-1-1-4-1-4-8-21 | 42 | CC5 | + | + (2059) | 12 | ≥256 | 0.5 | – |
PV66 | IC | UK | Acne | Atypical | 9-1-5-8-6-8-14-6 | 85 | S | + | + (2058) | ≥256 | ≥256 | 24 | – |
PRP-038 | IC | UK | Acne | Atypical | 9-1-4-8-6-8-14-14 | 70 | S | + | + (2059) | 32 | ≥256 | 0.38 | – |
PRP-039 | IC | UK | Acne | Atypical | 9-1-4-8-6-8-14-14 | 70 | S | + | + (2059) | ≥256 | ≥256 | 0.38 | – |
PRP-047 | II | Greece | Acne | II | 1-4-2-4-2-3-10-10 | 61 | CC6 | − | + (2059) | 0.25 | ≥256 | 2 | – |
PRP-078 | IA1 | Japan | Acne | IA | 1-1-1-3-7-1-22-2 | 86 | S | − | + (2059) | 0.125 | ≥256 | 24 | – |
434 | IA1 | Sweden | Acne | n/d | 5-1-1-3-1-1-1-1 | 20 | CC1 | − | − | ≥256 | ≥256 | nd | – |
226 | IA1 | Sweden | Acne | n/d | 1-1-1-3-1-1-2-3 | 31 | CC3 | − | − | 8 | ≥256 | nd | – |
HL097PA1 | IC | USA | Acne | n/d | 9-1-4-8-6-8-14-14 | 70 | S | + | + (2058) | nd | nd | nd | – |
HL045PA1 | IA1 | USA | Acne | n/d | 1-10-1-3-1-1-2-2 | 17 | CC3 | + | + (2058) | 16 | ≥256 | ≥256 | – |
HL007PA1 | IA1 | USA | Skin | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 24 | ≥256 | ≥256 | – |
HL038PA1 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-2-4 | 10 | CC3 | + | + (2059) | 4 | ≥256 | 0.875 | – |
HL099PA1 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 6 | ≥256 | ≥256 | – |
HL053PA1 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 6 | ≥256 | ≥256 | – |
HL056PA1 | IA1 | USA | Skin | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 16 | ≥256 | ≥256 | – |
HL074PA1 | IA1 | USA | Skin | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 24 | ≥256 | ≥256 | – |
HL096PA2 | IA1 | USA | Skin | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 6 | ≥256 | ≥256 | – |
HL043PA1 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 8 | ≥256 | ≥256 | – |
HL043PA2 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-2-2 | 3 | CC3 | + | + (2058) | 3 | ≥256 | ≥256 | – |
HL072PA1 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-1-1 | 1 | CC1 | + | + (2058) | 12 | ≥256 | ≥256 | – |
HL072PA2 | IA1 | USA | Acne | n/d | 1-1-1-3-1-1-1-1 | 1 | CC1 | + | + (2058) | 6 | ≥256 | ≥256 | – |
HL005PA1 | IA1 | USA | Skin | n/d | 1-1-1-3-1-1-5-2 | 11 | CC3 | + | + (2058) | 8 | ≥256 | ≥256 | – |
Antibody typing with type IA and type II monoclonal antibodies QUBPa1 and QUBPa2, respectively [12].
Tetracycline resistance MIC≥1.0 mg/L; erythromycin resistance MIC≥0.5 mg/L; clindamycin resistance MIC ≥0.25 mg/L.